<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490252</url>
  </required_header>
  <id_info>
    <org_study_id>FMD1</org_study_id>
    <nct_id>NCT04490252</nct_id>
  </id_info>
  <brief_title>Effects of Fasting Mimetic Diet on Nephropatic Patients</brief_title>
  <official_title>Effects of Fasting Mimetic Diet on Nephropatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fasting mimetic diet (FMD) showed positive effects on cardiovascular risks. Purpose of the&#xD;
      trial is to evaluate FMD effects on patients affected by chronic kidney disease (CKD),&#xD;
      through the stimulation of kidney stem cells and improving cardiovascular and metabolic&#xD;
      status.&#xD;
&#xD;
      From April 2018, the investigators enrolled 13 patients (7 male) with an history of primary&#xD;
      glomerulonephritis (GMN) and an eGFR between 60 ml/min and 30 ml/min. Exclusion criteria are:&#xD;
      age &lt;18 y.o., age&gt; 65 y.o., secondary GMN, severe heart failure (NYHA IV),ongoing infectious&#xD;
      diseases, ongoing neoplasia, hepatic diseases, COPD, inflammatory bowel disease, history of&#xD;
      stroke, history of acute coronary disease less than 3 months, pregnancy, refuse informed&#xD;
      consent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood stem cells level (CD133+, CD24+, CD45-, CD34+, CD309+) (%)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine (mg/dl)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea (mg/dl)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive C-protein (mg/L)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile: total cholesterol, LDL, HDL, triglyceride (mg/dl)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose (mg/dl)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iPTH (ng/ml)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total protein (g/L)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood insulin (mcUI/ml)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood uric acid (mg/dl)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation (%)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima-media thickness (mm)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR using CKD-EPI and MDRD (ml/min/1,73 m2)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal resistive index (dimensionless)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epicardial Adipose Tissue (cm)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck depression inventory II (BDI-II) (0 to 63 points)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI (kg/m^2)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Free diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Free diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasting mimetic diet for 5 days, next cycle after 25 days of free diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fasting mimetic diet</intervention_name>
    <description>Fasting mimetic diet for 5 days, another cycle after 25 days</description>
    <arm_group_label>FMD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of primary glomerulonephritis&#xD;
&#xD;
          -  eGFR between 60 ml/min and 30 ml/min&#xD;
&#xD;
          -  age between 18-65 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary GMN&#xD;
&#xD;
          -  severe heart failure (NYHA IV)&#xD;
&#xD;
          -  ongoing infectious diseases&#xD;
&#xD;
          -  ongoing neoplasia,&#xD;
&#xD;
          -  hepatic diseases&#xD;
&#xD;
          -  COPD,&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  history of stroke&#xD;
&#xD;
          -  history of acute coronary disease less than 3 months&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  refuse informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Lai, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome &quot;Sapienza&quot;- Department of Translational and Precision Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital &quot;Umberto I&quot;, University of Rome &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Silvia Lai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Fasting mimetic diet</keyword>
  <keyword>Kidney stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

